Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave.
June 22, 2021
Ryan Allway June 22nd, 2021 Psychedelics To drive brand awareness of, and access to, HaluGen’s Psychedelics Genetic Test Kit Vancouver, British Columbia–(Newsfile Corp. – June 22, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines... Read more
Ryan Allway June 17th, 2021 Psychedelics Vancouver, British Columbia–(Newsfile Corp. – June 17, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon”), a biotechnology company focused on developing psychedelic medicines to treat addiction, and Silo Wellness Inc. (CSE: SILO) (OTC: SILFF) (FSE:3K70) (“Silo Wellness”), a functional and psilocybin mushroom... Read more
